Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 438

1.

Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry (MRAD) and FDG PET/CT.

Crandall J, O JH, Gajwani P, Leal JP, Mawhinney DD, Sterzer F, Wahl RL.

J Nucl Med. 2018 Feb 9. pii: jnumed.117.204339. doi: 10.2967/jnumed.117.204339. [Epub ahead of print]

PMID:
29439011
2.

Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach.

Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH.

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):320-332. doi: 10.1016/j.jcmg.2017.11.019.

PMID:
29413441
3.

PERCIST in Perspective.

O JH, Wahl RL.

Nucl Med Mol Imaging. 2018 Feb;52(1):1-4. doi: 10.1007/s13139-017-0507-4. Epub 2017 Dec 18.

PMID:
29391906
4.

Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts.

Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL.

J Nucl Med. 2018 Jan 18. pii: jnumed.117.203299. doi: 10.2967/jnumed.117.203299. [Epub ahead of print]

PMID:
29348316
5.

Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms.

Mhlanga JC, Chirindel A, Lodge MA, Wahl RL, Subramaniam RM.

Nucl Med Commun. 2018 Feb;39(2):154-160. doi: 10.1097/MNM.0000000000000786.

PMID:
29227348
6.

Non-invasive methods for the assessment of brown adipose tissue in humans.

Chondronikola M, Beeman SC, Wahl RL.

J Physiol. 2018 Feb 1;596(3):363-378. doi: 10.1113/JP274255. Epub 2018 Jan 15.

PMID:
29119565
7.

DNA Repair After Exposure to Ionizing Radiation Is Not Error-Free.

Duncan JR, Lieber MR, Adachi N, Wahl RL.

J Nucl Med. 2018 Feb;59(2):348. doi: 10.2967/jnumed.117.197673. Epub 2017 Aug 3. No abstract available.

PMID:
28775198
8.

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D.

Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020.

PMID:
28371832
9.

Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability.

O JH, Jacene H, Luber B, Wang H, Huynh MH, Leal JP, Wahl RL.

J Nucl Med. 2017 Sep;58(9):1429-1434. doi: 10.2967/jnumed.117.189605. Epub 2017 Mar 30.

PMID:
28360211
10.

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL.

J Nucl Med. 2017 Sep;58(9):1421-1428. doi: 10.2967/jnumed.116.188839. Epub 2017 Mar 30.

PMID:
28360208
11.

The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA.

J Neurooncol. 2017 May;132(3):513-519. doi: 10.1007/s11060-017-2404-1. Epub 2017 Mar 17.

PMID:
28315063
12.

Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs.

Vicente EM, Lodge MA, Rowe SP, Wahl RL, Frey EC.

Med Phys. 2017 May;44(5):1707-1717. doi: 10.1002/mp.12164. Epub 2017 Mar 28.

PMID:
28207950
13.

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL.

EJNMMI Res. 2017 Dec;7(1):8. doi: 10.1186/s13550-017-0258-3. Epub 2017 Jan 19.

14.

Spatiotemporal distribution modeling of PET tracer uptake in solid tumors.

Soltani M, Sefidgar M, Bazmara H, Casey ME, Subramaniam RM, Wahl RL, Rahmim A.

Ann Nucl Med. 2017 Feb;31(2):109-124. doi: 10.1007/s12149-016-1141-4. Epub 2016 Dec 5.

PMID:
27921285
15.

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.

Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL.

Mol Imaging Biol. 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9.

PMID:
27798787
16.

Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer.

Yue J, Mauxion T, Reyes DK, Lodge MA, Hobbs RF, Rong X, Dong Y, Herman JM, Wahl RL, Geschwind JH, Frey EC.

Med Phys. 2016 Oct;43(10):5779.

17.

Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.

Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL.

J Nucl Med. 2017 Mar;58(3):393-398. doi: 10.2967/jnumed.116.178434. Epub 2016 Sep 29.

18.

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH.

J Clin Oncol. 2016 Aug 29. pii: JCO681858. [Epub ahead of print]

19.

Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans.

Chen KY, Cypess AM, Laughlin MR, Haft CR, Hu HH, Bredella MA, Enerbäck S, Kinahan PE, Lichtenbelt Wv, Lin FI, Sunderland JJ, Virtanen KA, Wahl RL.

Cell Metab. 2016 Aug 9;24(2):210-22. doi: 10.1016/j.cmet.2016.07.014. Review.

20.

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

Chu LC, Tsai HL, Wang H, Crandall J, Javadi MS, Wahl RL.

EJNMMI Res. 2016 Dec;6(1):42. doi: 10.1186/s13550-016-0194-7. Epub 2016 May 20.

21.

Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.

O JH, Lodge MA, Wahl RL.

Radiology. 2016 Aug;280(2):576-84. doi: 10.1148/radiol.2016142043. Epub 2016 Feb 24. Review.

22.

Quo Vadis: PET and Single-Photon Molecular Breast Imaging.

Wahl RL.

J Nucl Med. 2016 Feb;57 Suppl 1:3S-8S. doi: 10.2967/jnumed.115.159202. Review. No abstract available.

23.

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.

Hyun O J, Luber BS, Leal JP, Wang H, Bolejack V, Schuetze SM, Schwartz LH, Helman LJ, Reinke D, Baker LH, Wahl RL.

J Nucl Med. 2016 May;57(5):735-40. doi: 10.2967/jnumed.115.162412. Epub 2016 Jan 21.

24.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

25.

Racial Disparities in Asthma Hospitalizations Following Implementation of the Smoke-Free Air Law, Michigan, 2002-2012.

Marchese ME, Shamo F, Miller CE, Wahl RL, Li Y.

Prev Chronic Dis. 2015 Nov 19;12:E201. doi: 10.5888/pcd12.150144.

26.

Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.

Plyku D, Loeb DM, Prideaux AR, Baechler S, Wahl RL, Sgouros G, Hobbs RF.

Cancer Biother Radiopharm. 2015 Nov;30(9):369-79. doi: 10.1089/cbr.2014.1803.

27.

Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET.

Karakatsanis NA, Zhou Y, Lodge MA, Casey ME, Wahl RL, Zaidi H, Rahmim A.

Phys Med Biol. 2015 Nov 21;60(22):8643-73. doi: 10.1088/0031-9155/60/22/8643. Epub 2015 Oct 28.

29.

Optimal definition of biological tumor volume using positron emission tomography in an animal model.

Wu I, Wang H, Huso D, Wahl RL.

EJNMMI Res. 2015 Dec;5(1):58. doi: 10.1186/s13550-015-0134-y. Epub 2015 Oct 21.

30.

Hyaluronic acid-serum hydrogels rapidly restore metabolism of encapsulated stem cells and promote engraftment.

Chan AT, Karakas MF, Vakrou S, Afzal J, Rittenbach A, Lin X, Wahl RL, Pomper MG, Steenbergen CJ, Tsui BM, Elisseeff JH, Abraham MR.

Biomaterials. 2015 Dec;73:1-11. doi: 10.1016/j.biomaterials.2015.09.001. Epub 2015 Sep 4.

31.

Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab.

Wahl RL, Horner TJ, Lin TS, Kaminski MS.

J Nucl Med. 2015 Nov;56(11):1800-3. doi: 10.2967/jnumed.115.156190. Epub 2015 Sep 3.

32.

Metrology Standards for Quantitative Imaging Biomarkers.

Sullivan DC, Obuchowski NA, Kessler LG, Raunig DL, Gatsonis C, Huang EP, Kondratovich M, McShane LM, Reeves AP, Barboriak DP, Guimaraes AR, Wahl RL; RSNA-QIBA Metrology Working Group.

Radiology. 2015 Dec;277(3):813-25. doi: 10.1148/radiol.2015142202. Epub 2015 Aug 12.

33.

Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data.

Anizan N, Wang H, Zhou XC, Hobbs RF, Wahl RL, Frey EC.

EJNMMI Res. 2014 Dec;4(1):67. doi: 10.1186/s13550-014-0067-x. Epub 2014 Dec 16.

34.

Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?

Bravo PE, Luo HC, Pozios I, Zimmerman SL, Corona-Villalobos CP, Sorensen L, Kamel IR, Bluemke DA, Wahl RL, Abraham MR, Abraham TP.

Eur Heart J Cardiovasc Imaging. 2016 Mar;17(3):293-300. doi: 10.1093/ehjci/jev154. Epub 2015 Jun 14.

35.

Performance assessment of a NaI(Tl) gamma counter for PET applications with methods for improved quantitative accuracy and greater standardization.

Lodge MA, Holt DP, Kinahan PE, Wong DF, Wahl RL.

EJNMMI Phys. 2015 May;2. pii: 11. doi: 10.1186/s40658-015-0114-3.

36.

Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms.

Bravo PE, Tahari A, Pozios I, Luo HC, Bengel FM, Wahl RL, Abraham MR, Abraham TP.

J Nucl Cardiol. 2016 Dec;23(6):1304-1314. Epub 2015 May 20.

PMID:
25989730
37.

Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹In-Pentetreotide Quantitative SPECT/CT.

Rowe SP, Vicente E, Anizan N, Wang H, Leal JP, Lodge MA, Frey EC, Wahl RL.

J Nucl Med. 2015 Jul;56(7):985-8. doi: 10.2967/jnumed.115.155358. Epub 2015 May 14.

38.

Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts.

Baum RP, Wahl RL.

J Nucl Med. 2015 May;56 Suppl 2:2A-30. doi: 10.2967/jnm565abs. No abstract available.

39.

Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.

Chirindel A, Alluri KC, Chaudhry MA, Wahl RL, Pawlik TM, Herman JM, Subramaniam RM.

AJR Am J Roentgenol. 2015 May;204(5):1093-9. doi: 10.2214/AJR.14.13156.

PMID:
25905947
40.

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.

Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS.

J Nucl Med. 2015 Jun;56(6):955-61. doi: 10.2967/jnumed.115.158402. Epub 2015 Apr 16.

41.

Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experience.

Antoniou AJ, Raja S, El-Khouli R, Mena E, Lodge MA, Wahl RL, Clarke JO, Pasricha P, Ziessman HA.

J Nucl Med. 2015 May;56(5):721-7. doi: 10.2967/jnumed.114.152074. Epub 2015 Mar 12.

42.

Two-time-point FDG PET/CT: liver SULmean repeatability.

Tahari AK, Paidpally V, Chirindel A, Wahl RL, Subramaniam RM.

AJR Am J Roentgenol. 2015 Feb;204(2):402-7. doi: 10.2214/AJR.14.12719.

43.

18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.

Marcus C, Paidpally V, Antoniou A, Zaheer A, Wahl RL, Subramaniam RM.

J Nucl Med. 2015 Feb;56(2):204-8. doi: 10.2967/jnumed.114.147884. Epub 2015 Jan 22.

44.

Factors affecting the repeatability of gamma camera calibration for quantitative imaging applications using a sealed source.

Anizan N, Wang H, Zhou XC, Wahl RL, Frey EC.

Phys Med Biol. 2015 Feb 7;60(3):1325-37. doi: 10.1088/0031-9155/60/3/1325. Epub 2015 Jan 16.

45.

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V.

J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741. Epub 2014 Dec 4.

46.

Longitudinal myocardial blood flow gradient and CAD detection.

Valenta I, Wahl RL, Schindler TH.

Curr Cardiol Rep. 2015 Jan;17(1):550. doi: 10.1007/s11886-014-0550-z. Review.

PMID:
25417123
47.

Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma.

Alluri KC, Tahari AK, Wahl RL, Koch W, Chung CH, Subramaniam RM.

AJR Am J Roentgenol. 2014 Oct;203(4):897-903. doi: 10.2214/AJR.14.12497.

48.

18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters.

Mhlanga JC, Carrino JA, Lodge M, Wang H, Wahl RL.

Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2337-45. doi: 10.1007/s00259-014-2856-x. Epub 2014 Aug 19.

49.

Optimum lean body formulation for correction of standardized uptake value in PET imaging.

Tahari AK, Chien D, Azadi JR, Wahl RL.

J Nucl Med. 2014 Sep;55(9):1481-4. doi: 10.2967/jnumed.113.136986. Epub 2014 Jun 24.

50.

Quantitative assessment of myocardial blood flow--clinical and research applications.

Schindler TH, Quercioli A, Valenta I, Ambrosio G, Wahl RL, Dilsizian V.

Semin Nucl Med. 2014 Jul;44(4):274-93. doi: 10.1053/j.semnuclmed.2014.04.002. Review.

PMID:
24948151

Supplemental Content

Support Center